Determining Your Patient's Eligibility

The Oncotype DX® Breast Recurrence Score™ provides comprehensive and actionable direction across the spectrum of ER-positive, invasive breast cancer biology, predicting the likelihood of adjuvant therapy benefit as well as your patient’s 10-year risk of distant recurrence. This information will help to guide your recommendation to personalize treatment for each of your patients.

The Breast Recurrence Score is intended for use in all newly diagnosed patients with invasive breast cancer who are:

  • Node-negative or node-positive (1-3)
  • ER-positive
  • HER2-negative

 Breast Cancer Types

 

FOR ALL EARLY-STAGE, ER-POSITIVE, HER2-NEGATIVE,
NODE-NEGATIVE, AND NODE-POSITIVE (1–3) PATIENTS
WITH INVASIVE BREAST CANCER

By testing every eligible patient after surgery but before you discuss her treatment
plan, you can make recommendations with increased insight and confidence.

 

Reference Card
Patient selection considerations are based on data from the suite of Oncotype DX studies, including NSABP B-14, NSABP B-20, TransATAC, and SWOG 8814.4-7

 

REFERENCES

1. AJCC Cancer Staging Manual.
2. NCCN clinical practice guidelines in oncology V.2.2016.
3. Harris et al. J Clin Oncol. 2016.
4. Dowsett et al. J Clin Oncol. 2010.
5. Albain et al. Lancet Oncol. 2010.
6. Paik et al. N Engl J Med. 2004.
7. Paik et al. J Clin Oncol. 2006.
*NCCN and NCCN Guidelines are registered trademarks of the National Comprehensive Cancer Network. *ASCO is a registered trademark of the American Society of Clinical Oncology. NCCN and ASCO do not endorse any product or therapy.
Next: Genomic Health Leadership